Columvi
Payments companies reported to CMS as associated with Columvi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Columvi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Columvi
These are the largest totals companies reported as associated with Columvi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Haifaa Abdulhaq | Fresno, CA | Hematology & Oncology | $72,957.47 |
| Vincent Herrin | Jackson, MS | Hematology (Internal Medicine) | $31,294.04 |
| Mark Fesler | Saint Louis, MO | Hematology & Oncology | $28,788.97 |
| Matthew Lunning | Omaha, NE | Medical Oncology | $25,350.15 |
| Daniel Kerr II | Tampa, FL | Hematology & Oncology | $25,254.43 |
| Stacy Lewis | Portland, OR | Medical Oncology | $23,602.11 |
| Amitkumar Mehta | Birmingham, AL | Hematology & Oncology | $21,064.59 |
| Tara Graff | Clive, IA | Medical Oncology | $17,961.65 |
| Tycel Phillips | Duarte, CA | Hematology (Internal Medicine) | $17,474.55 |
| Nikesh Shah | Tampa, FL | Hematology & Oncology | $17,397.45 |
Prescribed Columvi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.